Sickness behaviors are host defense adaptations that arise from integrated autonomic outputs in response to activation of the innate immune system. These behaviors include fever, anorexia, and hyperalgesia intended to promote survival of the host when encountering pathogens. Cannabinoid (CB) receptor activation can induce hypothermia and attenuate LPS-evoked fever. The aim of the present study was to examine the role of CB1 receptors in the LPS-evoked febrile response. CB1 receptor-deficient (CB1 Ϫ/Ϫ ) mice did not display LPSevoked fever; likewise, pharmacological blockade of CB1 receptors in wild-type mice blocked LPS-evoked fever. This unresponsiveness is not limited to thermogenesis, as the animals were not hyperalgesic after LPS administration. A Toll-like receptor (TLR)3 agonist and viral mimetic polyinosinic:polycytidylic acid evoked a robust fever in CB1 Ϫ/Ϫ mice, suggesting TLR3-mediated responses are functional. LPS-evoked c-Fos activation in areas of the brain associated with the febrile response was evident in wild-type mice but not in CB1 Ϫ/Ϫ mice. Liver and spleen TLR4 mRNA were significantly lower in CB1 Ϫ/Ϫ mice compared with wild-type mice, and peritoneal macrophages from CB1 Ϫ/Ϫ mice did not release proinflammatory cytokines in response to LPS. These data indicate that CB1 receptors play a critical role in LPS-induced febrile responses through inhibiting TLR4-mediated cytokine production.
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endocannabinoid; Toll-like receptor; fever; cytokine FEVER IS AN IMPORTANT COMPONENT of the innate immune response; subjects that are prevented from developing fever have increased morbidity and mortality (24, 30) . Fever occurs when structural motifs on bacterial cell walls, e.g., LPS for gramnegative bacteria, or double-stranded viral DNA, are recognized by Toll-like receptors (TLRs) on cells of the innate immune system (2, 32) . LPS-evoked inflammation is via TLR4 activation, whereas viral moieties are recognized by TLR3. These signaling pathways are activated in monocytes and circulating or resident macrophages (e.g., Kupffer cells of the liver) to cause synthesis and release of a number of pyrogenic factors, including IL-1, IL-6, TNF-␣, and IFN␥. These cytokines signal to the brain to induce cyclooxygenase (COX) 2-dependent prostaglandin synthesis and additional cytokine synthesis in the brain (11) . The resulting thermoregulatory response consists of both hypothermic and hyperthermic components, depending upon pyrogen, dose, and ambient temperature (47) and is often accompanied by other components of the host defense response, including hyperalgesia, anorexia, and sickness behaviors (14) . Almost concurrently with the generation of a proinflammatory response is the production of several anti-inflammatory cytokines (e.g., IL-1 receptor antagonist, IL-10) and corticosteroids that limit the febrile response (7, 46) .
Innate immune febrile responses can be modified by endogenous cannabinoids (eCB) acting on cannabinoid receptors (CB 1 and CB 2 ) in the central nervous system and periphery. The best recognized eCBs are anandamide and 2-arachidonoylglycerol, which are synthesized from arachidonic acid derived from the membrane phospholipids (59) . In the central nervous system, eCBs are important modulators of synaptic strength, acting as retrograde signaling molecules and as ligands at CB and certain other receptors (9, 29) . The CB 1 receptor is highly expressed in the central and peripheral nervous system, on both neurons (27, 34) , and glial cells (55) , as well as on many peripheral tissues, including immune cells (6, 36, 42) , whereas the CB 2 receptor is highly expressed in immune tissue, such as macrophages, blood cells, and the spleen tissue with a much more limited expression in brain (4, 6, 36, 42, 43, 56) .
Various studies have demonstrated that cannabinoids have a role in thermoregulation. CB receptors do not appear to be involved in tonic physiological regulation of body temperature as blockade of CB 1 or CB 2 receptors does not alter body temperature (44, 54) ; however, CB 1 receptors appear to mediate the hypothermic component of the response to LPS, as intracerebroventricular administration of the CB 1 receptor antagonist rimonabant completely blocks this hypothermia (10, 12) . Presumably, this is mediated via activation of CB 1 receptors expressed in the preoptic anterior hypothalamus (18, 40, 44) . Interestingly, the eCB anandamide is without effect on body temperature when administered via this route, whereas it does cause hypothermia when given to the periphery, possibly via an action at non-CB receptors (8, 54) . Paradoxically, low doses of the CB agonists, ⌬ 9 -tetrahydrocannabinol (16, 52) or anandamide (20) , have also been shown to increase body temperature in rats. Similarly, the role of CBs in innate immune febrile responses is unclear. For example, HU210, a very potent CB 1 receptor agonist, attenuated LPS-induced plasma levels of IL-1␤, TNF-␣, IL-6, and IFN␥ and brain expression of IL-1␤ and TNF-␣ in the rat (45) . Likewise, WIN 55,212-2, another CB 1 receptor agonist, attenuated an LPS-evoked febrile response and reduced plasma IL-6 levels via CB 1 receptor activation. However, treatment with the CB 1 receptor antagonist, SR141716A attenuated LPS-evoked fever, a finding attributed to an inverse agonist effect of SR141716A (5) . The findings that either CB receptor agonists or antagonists may have similar effects, as well as possible differing access of various drugs to active sites prompted us to further examine the role of CB receptors in the febrile response to LPS. In this study, we explored the role of CB 1 receptors in the febrile response using CB 1 receptor-deficient (CB 1 Ϫ/Ϫ ) mice.
MATERIALS AND METHODS

Animals.
Wild-type male C57BL/6 mice and CB1 Ϫ/Ϫ mice (6 -10 wk old) on a C57BL/6 background were used. The CB1 Ϫ/Ϫ mouse colony was established from heterozygous CB1 ϩ/Ϫ C57BL/6N mice obtained from B. Lutz (University of Mainz, Germany) (35) and bred in our animal care facility with wild-type C57BL/6 mice (Charles River Laboratories, Montreal, QC, Canada) for at least six generations. All CB 1 Ϫ/Ϫ transgenic mice were genotyped using established protocols and were confirmed as homozygous CB1 receptor genedeficient animals prior to inclusion in the study. Immunohistochemical studies indicated that these mice do not express immunoreactive CB 1 receptor protein in the brain (27) or in the gastrointestinal tract (26) , and PCR analyses in our laboratory for genotyping indicate it is absent in tail or ear snips. Thus, the genetic deficiency appears to be highly penetrant throughout all tissues. Wild-type animals were either bred in our facility from heterozygous mice or were purchased from Charles River Laboratories and maintained for a minimum of 12 days in our facility before any experimentation. Results were similar between in-house bred and purchased animals. Animals were housed under specified pathogen-free conditions at 20 -22°C and maintained on a 12:12-h light-dark cycle (lights on at 7 AM) in plastic sawdust floor cages with free access to Purina Laboratory chow and tap water. These studies were approved by the University of Calgary Animal Care Committee, and all protocols were carried out in accordance with the guidelines of the Canadian Council on Animal Care.
Body temperature recording. Mice were anesthetized with halothane (induced at 4%, maintained at 2%), and silicone-coated temperature data loggers (SubCue, Calgary, AB, Canada) were surgically implanted into the abdomen. After a 7-day recovery, mice were acclimatized to an ambient temperature of 27°C for 18 h prior to experimentation, which is a temperature at which mice are capable of mounting a febrile response and show good sensitivity to LPS (49) . Core body temperature measurements were recorded every 15 min postsurgery until the termination of the experiment, when the data loggers were removed, and data were downloaded using SubCue Analyzer software. Animals were injected with pyrogen-free saline (1 ml/kg ip), LPS (Escherichia coli, serotype 026:B6; Sigma; 100 g/kg in saline) or polyinosinic:polycytidylic acid (PolyIC: Sigma; 1 mg/kg in saline) between 10:30 and 11:30 AM. Animals received both saline and one of the pyrogens in a cross-over design, with a minimum of 1 wk between experiments. The CB receptor antagonist AM251 (Tocris; in 2% DMSO, 1% Tween 80, in saline) was injected intraperitoneally at 1 mg/kg, 4 h prior to LPS administration to examine the role of CB 1 receptor blockade on LPS-induced fever responses.
Nociception studies. To evaluate the contribution of CB 1 receptors to LPS-induced hyperalgesia, mice were treated with either saline or LPS (100 g/kg ip) and 45 min later tested for pain (nociceptive) thresholds using a thermal analgesia meter. Briefly, mice were placed on a thermal analgesia meter (Columbus Instruments, Columbus, OH), which was set at 55°C. The time required for each subject to display the criterion response, defined as a lick of the hindpaws or a jump, was measured to the nearest 0.1 s and recorded as the pain threshold in seconds (22) . An arbitrary cut-off time of 60 s was implemented. The surface of the heated plate was cleaned with a 10% ethanol solution between subjects.
Tissue preparation for c-Fos and quantitative RT-PCR. To determine whether the CNS response to LPS was altered in CB 1 Ϫ/Ϫ animals, mice were treated with saline or LPS (100 g/kg ip), and 1 h later, the mice were quickly anesthetized with isoflurane and exsanguinated with systemic perfusion using 0.9% saline. Spleen and liver were removed and stored in RNAlater at Ϫ80°C until use. Brains were then perfused transcardially with 4% paraformaldehyde (PFA), postfixed overnight (4% PFA, 4°C), and cryoprotected in 20% sucrose at 4°C until histological assessment. Brains were frozen in Tissue-Tek O.C.T., and 40-m coronal cryostat sections were cut and incubated with rabbit anti-c-Fos antibody (1:1,000; AB5, PC38; Oncogene, San Diego, CA) for 48 h. Tissues were then washed in PBS 3 times for 10 min and then incubated in donkey anti-rabbit CY3 secondary antibody (1:100; Jackson, West Grove, PA) for 2 h at room temperature. Tissues were then washed again and mounted on slides with a bicarbonate-buffered glycerol (pH 8.6) and visualized via a Zeiss Axioplan fluorescence microscope and photographed with a digital camera (Sensys, Photometrics, Tucson, AZ). c-Fos immunoreactive nuclei were counted in a minimum of three nonadjacent sections for each animal in the area postrema, nucleus of the solitary tract, supraoptic nucleus, paraventricular nucleus, and the dorsal medial hypothalamus. Investigators were blinded to genotype and treatment during counting.
RNA preparation and quantitative RT-PCR. RNA extraction was performed using TRIzol reagent (Invitrogen, Carlsbad, CA). All samples collected had tissue weights between 100 and 200 mg, requiring 1 ml of TRIzol reagent for the homogenization process. The addition of chloroform, followed by centrifugation separated the solution into an aqueous and organic phase. RNA in the aqueous phase was precipitated using isopropyl alcohol. Total extracted RNA was purified with MessageClean (GenHunter, Nashville, TN) to remove potential DNA contamination. RNA pellets were redissolved in DNase/RNase-free water (Gibco, Gaithersburg, MD). Purified RNA concentrations were quantified by spectrophotometry (Biomate; Thermo Scientific, Waltham, MA) where A260/280 ratios obtained were 1.8 -2.1. Complementary DNA was synthesized from 2 g of purified RNA using random primers, Superscript II and RNaseOUT (Invitrogen). Quantitative RT-PCR was carried out on 96-well plates in 25-l reaction volumes with TaqMan Universal PCR Master Mix, TaqMan Gene Expression Assay for TLR4 or 20ϫ GAPDH as the endogenous control (Applied Biosystems, Foster City, CA). See Ref. 38 for a description of the primer sequences. The analysis was performed as a relative quantification using ABI Prism 7000 Sequence Detection System Software (Applied Biosystems). All samples were assayed in triplicate, normalized to the endogenous control, and calibrated to wild-type samples on each plate to reduce plate effects. A standard curve for TLR4 and GAPDH was also compared to assess PCR efficiency, in which both were validated to be within 10% of each other.
Cytokine production in response to LPS. To determine whether plasma cytokine induction by LPS was affected by CB1 deletion, CB1
Ϫ/Ϫ and wild-type mice were given saline or LPS (100 g/kg ip), and 90 min later, they were decapitated, the trunk blood was collected, and the serum was stored at Ϫ80°C until use. The samples were assayed using a Lincoplex Mouse Cytokine/Chemokine MCYTO-70K kit. The assay was conducted by Eve Technologies (Calgary, AB, Canada) to manufacturer's specifications.
LPS-induced synthesis and release of proinflammatory cytokines were also assessed in macrophages isolated from wild-type and CB1
Ϫ/Ϫ mice in response to LPS. PBS (5 ml) was injected into the peritoneal cavity of mice, and the abdomen was gently massaged for 1 min. The peritoneal fluid was withdrawn, centrifuged at 1,000 rpm for 5 min, the pelleted cells resuspended in RPMI medium (37°C), counted and adjusted to 2 ϫ 10 5 cells/ml. One-milliliter aliquots of the cell suspension were seeded into 12-well culture plates and incubated at 37°C for 4 h, at which point nonadherent cells were removed by gentle aspiration, and the adherent macrophage population was treated with 1 ml of RMPI (containing 10% FBS) Ϯ 1 g/ml E. coli LPS. Forty-eight hours later, the supernatant was collected, centrifuged, and stored at Ϫ80°C prior to cytokine determination. Levels of IL-6 and TNF-␣ were measured by sandwich enzyme-linked immunosorbent assay using paired antibodies from R&D Systems (Burlington, ON, Canada) following the manufacturers' instructions. Samples were assessed in duplicate and each assay had detection limits of 9 pg/ml.
Data analysis. Fever data were calculated as a fever index (°C ϫ h) between 60 min (a time after the stress-induced hyperthermia had subsided) and 360 min after LPS challenge and subjected to a paired or unpaired (as appropriate) Student's t-test for comparison of responses to vehicle and to pyrogen. Average baseline temperatures (time: Ϫ60 to 0 min) were also compared statistically using a Student's t-test before any analysis was performed to determine whether any baseline differences exist. All other data were analyzed using a Student's unpaired t-test. All data are presented as means Ϯ SE. Significance was accepted at P Ͻ 0.05.
RESULTS
Mice deficient for CB 1 receptors do not display an LPSevoked fever.
Wild-type and CB 1 Ϫ/Ϫ mice developed the expected transient stress-induced hyperthermia from the injection of both saline and LPS. The wild-type mice displayed a robust fever response peaking at around 120 min post-LPS injection at 1.9 Ϯ 0.2°C above baseline ( Fig. 1A; n ϭ 4) . In contrast, there was no febrile response in the CB 1 Ϫ/Ϫ mice following treatment with LPS ( Fig. 1B; n ϭ 6 ). Mice deficient for the CB 1 receptor had a baseline temperature ϳ0.5°C lower than wildtype mice; this deviation persisted throughout both light and dark periods of their cycle (data not shown). Analysis of fever indices indicated that responses of wild-type animals to LPS were significantly different (P Ͻ 0.05) than they were to saline, whereas fever indices of CB 1 Ϫ/Ϫ mice were not significantly different in response to saline and LPS (Fig. 1C) .
LPS-evoked fever is attenuated by a CB 1 receptor antagonist. One limitation of using loss of function approaches is the potential of developmental differences among strains. To confirm the physiological relevance of this phenomenon, we next evaluated the ability of the CB 1 receptor antagonist AM251 to attenuate fever responses to LPS in wild-type mice. Fig. 2, A and B shows that the LPS-induced febrile response was abolished in mice pretreated with AM251 compared with those mice pretreated with the vehicle prior to LPS (P Ͻ 0.05; n ϭ 5 or 6).
Mice deficient for CB 1 receptors do not develop LPS-evoked hyperalgesia. To determine whether the unresponsiveness to LPS was specific to the febrile response, we tested whether animals deficient in CB 1 receptors developed LPS-evoked hyperalgesia. Wild-type animals treated with LPS displayed a significant hyperalgesia compared with saline controls (P Ͻ 0.05; n ϭ 7), whereas in CB 1 Ϫ/Ϫ mice, LPS did not cause hyperalgesia (P Ͼ 0.05; n ϭ 6) (Fig. 3) . Thus, the absent febrile response was paralleled by a lack of the LPS-induced hyperalgesia. Interestingly, the CB 1 Ϫ/Ϫ mice showed lower baseline latency than untreated wild-type mice, similar to that observed in LPS-treated mice.
Mice deficient for CB 1 receptors display PolyIC-evoked fever. To determine whether the lack of fever in CB 1 Ϫ/Ϫ mice was restricted to LPS, a TLR4-directed ligand, we tested responses to the viral mimetic and TLR3 ligand, PolyIC. Wild-type animals displayed a long-lasting, febrile response (n ϭ 6 -9; Fig. 4A ). CB 1 Ϫ/Ϫ mice also produce a robust febrile response (n ϭ 5 or 6; Fig. 4B ), with fever indices for both genotypes being significantly greater for the PolyIC than for saline (P Ͼ 0.05; Fig. 4C ). Ϫ/Ϫ (B; n ϭ 6) mice treated with LPS (100 g/kg) or saline (time 0, arrow). C: fever indices derived from the experimental data in which LPS and saline temperature responses are compared for each set of experiments. *P Ͻ 0.05.
Mice deficient for CB 1 receptors express low levels of TLR4
and reduced cytokine production. Macrophages are known to express abundant TLR4 and are important in generating the febrile response (47) . Quantitative RT-PCR data indicate that CB 1 Ϫ/Ϫ mice (n ϭ 3) have lower message levels of TLR4 than wild-type (n ϭ 3) in spleen and liver after LPS treatment (Fig. 5, A and B) . Furthermore, LPS-treated CB 1 Ϫ/Ϫ mice (n ϭ 7) had lower plasma IL-6 and TNF-␣ levels compared with wild-type (n ϭ 6) mice (Fig. 6, A and  B) . To further investigate whether these lower levels were associated with the reduced TLR4 expression that we had identified in peripheral macrophages, we isolated macrophages and challenged them in vitro with LPS. Macrophages from CB 1 Ϫ/Ϫ mice generated significantly (P Ͻ 0.05) less IL-6 and TNF-␣ than did wild-type macrophages (Fig. 6, C and D) .
Mice deficient for CB 1 
do not produce LPS-evoked c-Fos expression.
LPS administration results in a characteristic increased c-Fos expression in areas of the brain associated with the febrile response, which is interpreted as neuronal activation within these brain areas. Wild-type animals had significant c-Fos expression in response to LPS compared with saline controls in the paraventricular nucleus, area postrema, nucleus of the solitary tract, supraoptic nucleus, and the dorsal medial hypothalamus (n ϭ 6; Fig. 7 ). In CB 1 Ϫ/Ϫ mice, there was no significant difference (n ϭ 6; P Ͼ 0.05) between saline and LPS treatment in any of these areas, a response consistent with the relative lack of effect of LPS on body temperature in these animals. Fig. 8 provides examples of photomicrographs from the hypothalamus, where a clear increase in c-Fos expression is seen in wild-type animals, but no increase is seen in the CB 1 Ϫ/Ϫ mice in the same area after LPS.
DISCUSSION
The present study indicates that CB 1 receptors are necessary for both the induction of the febrile response and the hyperalgesic response to LPS in mice. Wild-type animals given a low dose of LPS (100 g/kg ip) mounted a robust febrile response lasting 5 h; in contrast, CB 1 Ϫ/Ϫ mice or wild-type mice treated with a CB 1 receptor antagonist had no fever, despite retaining the ability to initiate a rapid thermogenic response to the injection stress and to TLR3 activation. In keeping with the lack of fever, CNS areas usually activated during fever did not display the characteristic c-Fos activation seen in wild-type animals. The reduced responsiveness to LPS may be due to downregulated TLR4 receptors in peripheral immune cells, as TLR mRNA was reduced and proinflammatory cytokine levels were markedly reduced after LPS in the CB 1 receptor knockouts compared with those measured in wild-type mice. The inability of mice lacking CB 1 receptors to mount a febrile response is in agreement with the work of Benamar et al. (5) in which administration of the CB 1 receptor antagonist SR141716A suppressed LPS-evoked fever in rats (5) . As genetic mutants may develop compensatory mechanisms, we also showed that mice treated with the CB 1 receptor antagonist AM251 were unable to mount a fever. Thus, our data from mice align with those obtained previously in rats. Our experiments were carried out at an ambient temperature that was permissive for the development of a fever in the mice. However, at lower ambient temperatures, the thermoregulatory response includes a significant hypothermia (49) . Given that this component of the response is dependent upon CB 1 receptors (54), it is likely that it would be abolished in CB 1 Ϫ/Ϫ mice. However, evidence for a critical role for brain CB 1 receptors in LPS-induced hypothermia was obtained by blocking central CB 1 receptors with intracerebroventricular injection of a CB 1 receptor antagonist (Rimonabant), whereas our results implicate a possible peripheral TLR4-dependent mechanism. Thus, more than one mechanism could be involved.
The eCB system is expressed throughout pain pathways and is thought to play an important role in modulating pain. CB 1 and CB 2 receptors suppress pain processing and prevent inflammation at multiple levels of the central and peripheral nervous system (3). LPS administration is associated with early hyperalgesia, mediated by IL-1␤ and TNF-␣, released from liver Kupffer cells to activate the CNS via the hepatic vagus (33, 60 -62) . We evaluated LPS-evoked hyperalgesia to determine whether this response was mediated by CB 1 receptors and demonstrated that mice deficient for CB 1 receptors did not display the expected hyperalgesia, compared with salinetreated controls. Taken together with the fever data, it would appear that the hyperalgesic pathways normally responsive to LPS are not being activated in CB 1 Ϫ/Ϫ mice, suggesting there is a deficiency in TLR4 receptor recognition to LPS. In addition to the early hyperalgesia studied here, in rats, LPS administration results in a later, longer-lasting hypoalgesia response (48, 51, 63) ; if a similar response were to exist in mice, it would be of interest to determine whether this phase of sensory responding is also altered in CB 1 Ϫ/Ϫ mice. CB 1 Ϫ/Ϫ mice also show baseline hyperalgesia, which is in keeping with the known action of CB 1 receptors in suppressing pain. This is in accord with the increased basal pain sensitivity reported for mice with selective deletion of CB 1 in nociceptive sensory neurons (1), although contradictory reports exist (64) . Although it is possible that their lack of response to LPS is due to a ceiling effect, we believe that this is unlikely, as our preliminary experiments indicated that more rapid paw withdrawal was evident when the temperature was elevated. Thus, the animals appear capable of exhibiting greater sensory responses. In future experiments, it would be interesting to determine whether a hyperalgesic response was present to PolyIC, in accord with the preservation of the febrile response in these CB 1 knockout animals. However, our findings still shed little light on how the unquestioned suppression of the Ϫ/Ϫ mice exposed to LPS or saline (n ϭ 5-7/group). *P Ͻ 0.05. innate immune response to CB 1 receptor activation becomes similarly suppressed in the absence of these receptors. Whether there are different populations of receptors important in the two responses or whether there are occult receptor populations that respond to CB 1 receptor ligands remains to be determined.
The innate immune system has the ability to detect many different types of pathogens (2) . PolyIC is a double-stranded RNA that is capable of evoking cellular responses via the TLR3 receptor and is used as a model of viral infection (58) . Administration of PolyIC to rats evokes a febrile response similar to LPS (15, 19) . PolyIC, in common with LPS, results in a IL-1␤-and prostaglandin-dependent fever, with enhanced plasma IL-6 and TNF-␣, but with a different time profile to LPS (19) . In addition to the proinflammatory cytokines released by TLR4 activation, PolyIC is also a potent inducer of the cytokine, IFN␥ (13, 37) . To determine whether TLR3-induced febrile responses were intact in the absence of CB 1 receptors, we treated wild-type and CB 1 Ϫ/Ϫ mice with PolyIC. A robust febrile response was observed in both wild-type and CB 1 Ϫ/Ϫ mice similar to that observed in rats (19) and guinea pigs (58) . This indicates that TLR3-mediated responses are functional and suggest that COX pathways involved in fever are intact in CB 1 Ϫ/Ϫ mice (58) . Furthermore, it is evident that the effector mechanisms responsible for thermogenesis in the CB 1 Ϫ/Ϫ animals are unaffected. The ability of CB 1 Ϫ/Ϫ mice to mount a febrile response to TLR3 stimulation but not to LPS would suggest that these animals have altered TLR4 signaling. Ample evidence indicates that TLR4 receptors are critical for recognition of the LPS molecule (reviewed in Ref. 2) and are necessary for development of LPS fever in mice (53) . Our data indicate that TLR4 levels are significantly reduced in mice deficient for CB 1 receptors in two tissues important for generation of cytokines involved in the febrile response, the liver and the spleen. In keeping with the lowered message levels of TLR4 in myeloid cells (28) , LPS stimulation of macrophages in vitro failed to induce proinflammatory cytokine production and plasma levels of two cytokines important in the febrile response, IL-6 and TNF-␣, which were reduced in CB 1 Ϫ/Ϫ mice. These data would suggest that CB 1 Ϫ/Ϫ mice have reduced or dysfunctional TLR4 expression or signaling to account for the lack of a LPS response.
Deletion of CB 1 receptors has been previously reported to alter expression or activity of a number of other receptors (17, 31, 39, 41, 50) . It is possible that the CB 1 Ϫ/Ϫ mice are lacking an intronic enhancer that is being used by the TLR4 gene (21) . With respect to this, it may be significant that Cnr1, the gene that encodes the CB 1 receptor and Tlr4, which encodes the TLR4 receptor both reside on chromosome 4 in the mouse. The LPS signaling complex also incorporates the signaling molecules CD-14 and MD-2 (2), but the genes that encode these molecules are found on chromosome 18 and 1, respectively, in the mouse, making flanking gene effects less likely for them. Developmental alterations in the CB 1 receptor knockout cannot be totally discounted (23) , but the fact that the CB 1 Ϫ/Ϫ mice were backcrossed for five generations in Germany prior to the first publication of research on them in 2002 (35) and that they were backcrossed with the same wild-type strain for a further six generations in our facilities makes this less likely. To more directly address this issue, we administered acutely a CB 1 receptor antagonist to wild-type mice and were also able to block the febrile response. This suggests some sort of functional relationship between the CB 1 and TLR4 receptor and that our finding is not an aberration of the knockout. Whether the acute blockade of CB 1 receptors by AM251 causes an acute downregulation of TLR4 signaling is not known; some CB 1 receptor antagonists, including AM251, have interesting properties, including inverse agonism, and once more is known of possible signaling pathways that may link CB 1 receptors and TLR4 receptors, this may be a profitable avenue of investigation.
Perspectives and Significance
Generation of a fever and associated host responses are important defenses against infection. CB 1 receptor antagonists have been evaluated in the treatment of metabolic disorders; however, our data suggest that CB 1 receptor blockade may prevent important innate immune febrile responses to bacterial challenge. This could compromise health and raise questions concerning possible chronic use of CB 1 receptor antagonists in such treatments targeted at metabolic disorders. Conversely, acute CB 1 receptor blockade may be of clinical use as a "TLR4 antagonist", for example, in multiorgan failure associated with sepsis (32) . Indeed, CB 1 receptor antagonists have already been reported to improve survival in a LPS model of septic shock (57) . Given the widespread distribution of CB 1 receptors in the body and their involvement in so many body functions, pharmacological approaches targeted at receptor function may not be ideal, whereas approaches targeting ligand synthesis and degradation (25) may be more promising.
